FDA president and Executive Committee elections 2020
Nominations are now open for the election of the FDA president and members of the FDA Executive Committee. As members of both the FDA and UNISON, MiP members are entitled to stand for election, nominate candidates and vote in both elections.
FDA Executive Committee
MiP has four seats on the FDA Executive Committee. MiP members can only nominate candidates from within the MiP constituency, and each nomination must be signed by at least two MiP members or by the MiP National Committee. If more than four candidates are nominated, a postal ballot will be held. Members elected to represent the MiP constituency will serve for a two-year term, from 1 June 2020 to 31 May 2022.
You can download the nomination form for the Executive Committee elections here.
FDA President
MiP members can also nominate candidates, from any constituency of the FDA, for the post of the FDA president. Candidates will need at least 30 nominations to stand, including at least five from three different constituencies. If more than one candidate is successfully nominated, a postal ballot will be held. The president will service a two-year term, from 1 June 2020 to 31 May 2022.
You can download the nomination form for the election of the FDA president here.
Nominations for both elections close at 5pm on Friday 6 March 2020.
You can read more about the FDA’s structure and the role of the president and Executive Committee on the FDA’s website.
Related News
-
MiP responds to the Ten-Year Health Plan
Government must get a grip of chaotic reorganisation if NHS Ten-Year Plan is to succeed, says MiP.
-
Board-level managers given lower pay rise as new pay system kicks in
MiP has warned the government to “get senior staff on board” after executive-level NHS managers in England were given a 3.25% pay rise—lower than other health service staff.
-
Funding settlement a “good turn” says NHS England chief—but is it enough?
The chancellor, Rachel Reeves has unveiled what she called a “record cash investment” in the NHS in England as part of the government’s spending review. The settlement will see NHS spending rise by around 3% above inflation during this parliament.